LYFJOS
LIVE

Serial Number

79113158

Owner

Lyfjos GmbH

Attorney

William H. Cox

Filing Date

Feb 25, 2012

Add to watchlist:

No watchlists yet
View on USPTO

LYFJOS Trademark

Serial Number: 79113158 • Registration: 4437873

LYFJOS is a trademark filed by Lyfjos GmbH on February 25, 2012. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Lyfjos GmbH

Arterstrasse 26

Entity Type: 16

Trademark Details

Filing Date

February 25, 2012

Registration Date

November 26, 2013

Published for Opposition

September 10, 2013

Cancellation Date

February 26, 2022

Goods & Services

Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signaling, checking, supervision, life saving and teaching apparatus and instruments, namely, remote sensing and diagnostic apparatuses that are used for monitoring any kind of test subjects and study cohorts as well as tissue samples or liquids from humans, animals or plants, particularly for the chemical, pharmaceutical, biochemistry, biotechnology and food industries; apparatus and instruments for diagnostic, analytical, and testing purposes for scientific use, particularly for chemical and physical analyses, for the development of medicines, for gene identification particularly in relation to unusual DNA sequences or that of the sick, for cell research, for biopsies of tissue, isolated cells, metastatic cells, bone marrow cells, body fluid cells particularly blood, stem cells and cloned cells; apparatus and instruments for directing, switching, transforming, storing, regulating and controlling electricity, particularly testing apparatus and electric and electronic machines, namely, robotics to handle specific and routine laboratory work; apparatus, equipment and installations, namely, disposable apparatus, disposable installations and disposable equipment for bioreactors for cell cultures, for pharmaceutical and biological procedures, support containers for bags, small bags and containers for cell cultures, pharmaceutical and biological procedures; apparatus, machines and fermenters for bacteria and cell cultures, particularly apparatus and machines for the cultivation of cell cultures, namely, bioreactors; soldering apparatus for sterile tubes, computers, computer programs, computer software and peripheral devices; dosing apparatus, fermentation apparatus, physical apparatus and instruments, namely, densitometers, chromatographs, conductance meters and spectrometers, temperature indicators, vacuum indicators, namely, vacuum gauges and flow meters, particularly for the chemical, pharmaceutical, biochemistry, biotechnology and food industries all not for medical use; apparatus and instruments for collecting liquid samples, particularly of solutions containing cells, cell cultures and cell lines for scientific or laboratory use; valve heads with pressure gauges, tubes, hoses, pipes, cisterns, tanks and tank closures sold as an integral part of densitometers, chromatographs, conductance meters and spectrometers, particularly for the chemical, pharmaceutical, biochemistry, biotechnology and food industries

Cell cultures, cell culture lines particularly of human cells, mammalian cells and insect cells and cell culture media for use in propagation in vitro all particularly for pharmaceutical and medical use; biological cells for medical use; micro-organism cultures for cultivating human, animal or insect cell lines, namely, isolated cells from humans, animals or plants, particularly for pharmaceutical and medical use; cell media, cell cultures for cultivating human, animal or insect cell lines, and cell lines, namely, isolated cells from humans, animals or plants, particularly for pharmaceutical and medical use; proteins, particularly for pharmaceutical and medical use, namely, hormones, ion channel ligands and G-protein interactive molecules that influence signal transduction; protein reagents, particularly for pharmaceutical and medical use; diagnostic reagents, particularly for pharmaceutical and medical use; cell control agents, namely, growth factors and inhibitors, particularly for pharmaceutical and medical use; amino acids, deoxyribonucleic acids (DNA), DNA fragments, DNA sequences, particularly for pharmaceutical and medical use; cell growth factor preparations, namely, Erythropoetin (EPO), Angiopoietin (Ang), Adrenomedullin (AM), transforming growth factor preparations, Interleukins, Insulin-like growth factor (IGF) preparations, and Foetal Bovine Somatotrophin that can be used in conjunction with therapy or diagnostics with human tissue, particularly for pharmaceutical and medical use; biotechnological reagents, particularly for pharmaceutical and medical use; gene cloning material, namely, a DNA vector or enzyme or active molecule that can be used in therapy or diagnostics of human or animal patients, particularly for pharmaceutical and medical use; chemicals, namely, chemical substances that modulate signaling cascades in vertebrates, for pharmaceutical and medical use; preparations with antibodies, namely, natural occurring or genetically engineered antibodies or fragments of antibodies that interact with signaling cascades in vertebrates, particularly for pharmaceutical and medical use; biological kits, namely, polyclonal, monoclonal or fragements of antibodies that can be used to detect certain epitopes or signaling events for disease testing as well as functional testing in the case of occurring variations of the epitope of interest, particularly for pharmaceutical and medical use; serums, antibodies, pharmaceutical and veterinary preparations, particularly natural pharmaceutical and veterinary products and preparations, all for the prevention of diseases like malaria that interact with animal and human hosts as well as the health risk assessment to conditions that arise from the genetic variation of the human patient; alcohols for pharmaceutical purposes; biological preparations for medical and veterinary use for the treatment of anemia deficiencies, inborn error of metabolism, genetic disorders and cancer; sanitary preparations for medical purposes; nutritional supplements for medical use; foodstuffs for medical purposes, namely, food additives as metabolic supplementations, namely, essential fatty acids, biotin, folic acid, essential amino acids; dietetic beverages adapted for medical use; dietetic foods and dietetic foodstuffs, namely, pasta, crackers, chips, sauces and spicery adapted for medical use; medicinal alcohol; oils for medical use, namely, olive oil, castor oil, canola oil and linseed oil; mineral water salts for medical purposes; salts for medical purposes, namely, medicated bath salts; salts for mineral water baths for medical purposes; medicinal herbal teas; dietetic sugar for medical use; food for babies; medical plasters, and medical dressings; material for stopping teeth, dental wax; disinfectants for sanitary purposes; preparations for destroying vermin; fungicides, herbicides

Scientific research and professional consulting in relation to chemistry, pharmacology, biology, biochemistry, molecular biology, biotechnology, neurology, electrophysiology, genetic engineering, pharmacology, pharmaceuticals, the technological construction of sterile installations, procedural and production technology and laboratory apparatus; scientific research and development, particularly relating to cell cultures and cell current measurements as well as electrophysiology measurements; scientific research and professional consulting as related to processes for the analysis and development of a method to collect data from analyzing devices or third party databases, extract information according to specific criteria and transfer the data in a ready-to use form to an online database with specific interfaces to the user to generate computational models out of wet lab data; design and development, particularly relating to computer software for the analysis of cell cultures, for pharmaceutical agents, for the exploration, analysis and treatment of hereditary diseases and for pharmaceutical research; identification, namely, safety testing and functional analysis of targets for the development of medicines; exploration, namely, scientific research data recording services into the causes of human and animal diseases; exploration, namely, scientific research and data recording services into the development of metastatic cells; exploration, namely, assessing the in-vivo and in-vitro effect of moderating or potentiating cell signaling molecules into the influence of various substances on cell signals, cell growth, the dissemination and separation of molecules in cells; research and development of medicines, genetic research, particularly for individual cells, cell cultures and cell culture lines; providing of cells, cell cultures and cell lines for scientific purposes by means of renting and leasing cells, cell cultures and cell lines; providing DNA for scientific purposes to others through rental or leasing; laboratory services for scientific purposes, particularly analyzing, testing and diagnosing cells, cell cultures and cell lines as well as for product development of cloned antibodies; industrial analysis and research services in the field of pain research, cancer research, immune system research and research in human metabolism; scientific and technological services, namely, pain research, cancer research, immune system research and research in human metabolism and research and design services relating thereto

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Sep 11, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Sep 11, 2022 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jan 29, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Dec 29, 2021 INTS
INVALIDATION PROCESSED
Dec 29, 2021 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 26, 2021 INTR
CANCELLED SECTION 71
Feb 26, 2021 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 26, 2018 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 3, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 27, 2014 FICS
FINAL DISPOSITION PROCESSED
Feb 27, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 26, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 26, 2013 R.PR
NOTIFICATION PROCESSED BY IB
Sep 15, 2013 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 10, 2013 NPUB
PUBLISHED FOR OPPOSITION
Sep 10, 2013 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 28, 2013 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 28, 2013 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 21, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 7, 2013 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 5, 2013 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 2, 2013 XAEC
ASSIGNED TO LIE
Aug 2, 2013 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 2, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 2, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 2, 2013 CNEA
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Jul 31, 2013 RDX3
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Jul 31, 2013 RDX1
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Jul 31, 2013 RRDX
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 25, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2013 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 24, 2013 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 26, 2013 GNFN
FINAL REFUSAL E-MAILED
Feb 26, 2013 GNFR
FINAL REFUSAL WRITTEN
Feb 26, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 31, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 31, 2013 TROA
REFUSAL PROCESSED BY IB
Aug 29, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 6, 2012 RFCS
REFUSAL PROCESSED BY MPU
Aug 6, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 4, 2012 RFCR
NON-FINAL ACTION WRITTEN
Aug 3, 2012 CNRT
APPLICATION FILING RECEIPT MAILED
Jun 19, 2012 MAFR
ASSIGNED TO EXAMINER
Jun 15, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 15, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 14, 2012 REPR